Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HcKCR1 (kalium channelrhodopsin 1) is a natural light-gated, potassium-selective channelrhodopsin originally discovered in the stramenopile protist *Hyphochytrium catenoides*. It functions as a highly selective potassium channel that opens rapidly (in less than 1 ms) upon illumination with green light (peak activation around 540 nm). Unlike classical potassium channels, HcKCR1 lacks the canonical TVGYG selectivity filter, instead utilizing an alternative asymmetric selectivity gate to discriminate potassium from sodium. When expressed in excitable cells such as neurons or cardiomyocytes via adeno-associated virus (AAV) vectors, photoactivation of HcKCR1 drives potassium efflux, leading to membrane hyperpolarization and robust silencing of action potentials. HcKCR1 is widely investigated as an inhibitory optogenetic tool and a potential gene therapy candidate for the treatment of hyperexcitability-associated neurological and cardiac disorders, including epilepsy, Parkinson's disease, neuropathic pain, and cardiac arrhythmias.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HcKCR1.